Clinical Trials
21 trialsNCT05751798 2026-06-04
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
OSE Immunotherapeutics
Phase 1/2 Recruiting
NCT02465060 2026-06-03
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07583771 2026-05-13
A Phase â… Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1 Not yet recruiting
NCT05509751 2026-04-28
SOAR
University of Toronto
Phase NA Active not recruiting
NCT01441089 2026-04-14
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
National Institutes of Health Clinical Center (CC)
Recruiting
NCT04081779 2026-04-08
Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study
Fred Hutchinson Cancer Center
Phase NA Completed
NCT04478318 2026-03-10
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
University of California, Davis
Phase NA Active not recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT02704832 2026-01-30
PREPARE
Institut Bergonié
Phase NA Completed
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT00508443 2026-01-15
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT07286539 2025-12-16
PEPOH
University of Salamanca
Phase NA Not yet recruiting
NCT03702309 2025-11-26
LIBERATE
University Health Network, Toronto
Recruiting
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT05565417 2025-10-16
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
Phase 1/2 Active not recruiting
NCT06582849 2025-08-26
EARN
Washington University School of Medicine
Phase NA Completed
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT03862131 2025-07-29
PROACT
Washington University School of Medicine
Phase 2 Terminated
NCT06347939 2025-07-17
MECRIS
Region Skane
Recruiting
NCT03884556 2025-07-02
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT02821793 2025-07-01
PRIORITY
Institut Bergonié
Completed